#1What if we could make RNA 8 greenight accessible to everyone?#2Disclaimer Caution Regarding Forward Looking Statements Certain statements included in this Investor Presentation ("Presentation") that are not historical facts are forward-looking statements for purposes of US law. Forward-looking statements generally are accompanied by words such as "believe," "may," "will," "estimate," "continue," "anticipate," "intend," "expect," "should," "would," "plan," "pipeline", "predict," "project," "forecast," "potential," "seem," "seek," "strategy," "future," "outlook," "opportunity," "should," "would," "will be," "will continue," "will likely result" and similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, statements regarding operating results, product field test clinical trials, future liquidity, the proposed transaction between Environmental Impact Acquisition Corporation ("ENVI") and GreenLight, including statements as to the expected timing, funding, completion and effects of the Proposed Business Combination or other steps or transactions associated with it and financial estimates, forecasts, and performance metrics and projections of market opportunity. These statements are based on various assumptions, whether or not identified in this Presentation, and on the current expectations of the respective management of GreenLight and Environmental Impact Acquisition Corporation ("ENVI") and are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on by an investor as, a guarantee, an assurance, a prediction, or a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. Many actual events and circumstances are beyond the control of GreenLight and Environmental Impact Acquisition Corporation ("ENVI"). These forward-looking statements are subject to a number of risks and uncertainties, including the extent of the impact of the COVID-19 pandemic, changes in domestic and foreign business, market, financial, political, and legal conditions; the inability of the parties to successfully or timely consummate the Proposed Business Combination, including the risk that any regulatory approvals are not obtained, are delayed or are subject to unanticipated conditions that could adversely affect the combined company or the expected benefits of the Proposed Business Combination or that the approval of the stockholders of Environmental Impact Acquisition Corporation ("ENVI") or GreenLight is not obtained; failure to realize the anticipated benefits of the Proposed Business Combination; risks relating to the uncertainty of the projected financial information with respect to GreenLight; risks related to the development, trial and regulatory approval of GreenLight's products; the effects of competition on GreenLight's business; the amount of redemption requests made by Environmental Impact Acquisition Corporation's ("ENVI") stockholders; and the ability of Environmental Impact Acquisition Corporation ("ENVI") or GreenLight to issue equity or equity-linked securities or obtain debt financing in connection with the Proposed Business Combination or in the future. There may be additional risks that neither Environmental Impact Acquisition Corporation ("ENVI") nor GreenLight presently know, or that Environmental Impact Acquisition Corporation ("ENVI") nor GreenLight currently believe are immaterial, that could also cause actual results to differ from those contained in the forward-looking statements. In addition, forward-looking statements reflect Environmental Impact Acquisition Corporation's ("ENVI") and GreenLight's expectations, plans, or forecasts of future events and views as of the date of this Presentation. Environmental Impact Acquisition Corporation ("ENVI") and GreenLight anticipate that subsequent events and developments will cause Environmental Impact Acquisition Corporation's ("ENVI") and GreenLight's assessments to change. However, while Environmental Impact Acquisition Corporation ("ENVI") and GreenLight may elect to update these forward-looking statements at some point in the future, Environmental Impact Acquisition Corporation ("ENVI") and GreenLight specifically disclaim any obligation to do so. These forward-looking statements should not be relied upon as representing Environmental Impact Acquisition Corporation's ("ENVI") and GreenLight's assessments of any date after the date of his Presentation. Accordingly, undue reliance should not be placed upon the forward-looking statements. Investor Presentation | © 2021 GreenLight Biosciences. All rights reserved. GreenLight confidential. 2#3Disclaimer Use of projections This Presentation contains projected financial information with respect to GreenLight. Such projected financial information constitutes forward-looking information and is for illustrative purposes only. Financial projections should not be relied upon as necessarily being indicative of future results. The assumptions and estimates underlying such financial forecast information are inherently uncertain and are subject to a wide variety of significant business, economic, competitive, and other risks and uncertainties. See "Forward-Looking Statements" above. Actual results may differ materially from the results contemplated by the financial forecast information contained in this Presentation, and the inclusion of such information in this Presentation should not be regarded as a representation by any person that the results reflected in such forecasts will be achieved. No representations or warranties No representations or warranties, express or implied are given in, or in respect of, this Presentation. To the fullest extent permitted by law in no circumstances will Environmental Impact Acquisition Corporation ("ENVI"), GreenLight or any of their respective subsidiaries, stockholders, affiliates, representatives, directors, officers, employees, advisers, or agents by responsible or liable for a direct, indirect, or consequential loss or loss of profit arising from the use of this Presentation its contents, its omissions, reliance on the information contained within it, or on opinions communicated in relation thereto or otherwise arising in connection therewith. Industry and market data used in this Presentation have been obtained from third-party industry publications and sources as well as from research reports prepared for other purposes. Neither Environmental Impact Acquisition Corporation ("ENVI") nor GreenLight has independently verified the data obtained from these sources and cannot assure you of the data's accuracy or completeness. This data is subject to change. In addition, this Presentation does not purport to be all-inclusive or to contain all of the information that may be required to make a full analysis of GreenLight or the Proposed Business Combination. Viewers of this Presentation should each make their own evaluation of GreenLight and of the relevance and adequacy of the information and should make such other investigations as they deem necessary. No offer or solicitation This Presentation is for informational purposes only and is not an offer to sell, or the solicitation of an offer to buy, any securities, nor shall there be any sale of securities in any states or jurisdictions in which such offer, solicitation or sale would be unlawful. This Presentation has been prepared to assist interested parties in making their own evaluation with respect to a potential business combination between GreenLight Biosciences, Inc. ("GreenLight") and Environmental Impact Acquisition Corporation ("ENVI") and the related transactions (the "Proposed Business Combination") and for no other purpose. Neither the Securities and Exchange Commission nor any securities commission of any other U.S. or non-U.S. jurisdiction has approved or disapproved of the Proposed Business Combination or determined that this Presentation is truthful or complete. Any representation to the contrary is a criminal offense. Investor Presentation | © 2021 GreenLight Biosciences. All rights reserved. GreenLight confidential. 3#4Disclaimer Trademarks All trademarks, service marks, and trade names of Environmental Impact Acquisition Corporation ("ENVI") or GreenLight or their respective affiliates used herein are trademarks, service marks, or registered trade names of Environmental Impact Acquisition Corporation ("ENVI") or GreenLight, respectively, as noted herein. Any other product, company names, or logos mentioned herein are the trademarks and/or intellectual property of their respective owners, and their use is not intended to, and does not imply, a relationship, endorsement, sponsorship or future dealings with Environmental Impact Acquisition Corporation ("ENVI") or GreenLight. Participants in the solicitation GreenLight, Environmental Impact Acquisition Corporation ("ENVI") and their respective directors and certain of their respective executive officers and other members of management and employees may be considered participants in the solicitation of proxies with respect to the Proposed Business Combination. Information about the directors and executive officers of Environmental Impact Acquisition Corporation ("ENVI") is in its Form 10-K for the fiscal year ended December 31, 2020 and information about GreenLight's directors, officers and employees can be found at www.greenlightbiosciences.com. Additional information regarding the participants in the proxy solicitation and a description of their direct interests, by security holdings or otherwise, will be set forth in the Registration Statement and other relevant materials to be filed with the SEC regarding the Proposed Business Combination. Stockholders, potential investors and other interested persons should read the Registration Statement carefully before making any voting or investment decisions. These documents, when available, can be obtained free of charge from the sources indicated above. Financial information The financial information and data contained in this Presentation is unaudited and does not conform to Regulation S-X. Accordingly, such information and data may not be included in, may be adjusted in, or may be presented differently in, any proxy statement/prospectus or registration statement or other report or document to be filed or furnished by Environmental Impact Acquisition Corporation ("ENVI") with the SEC. Some of the financial information and data contained in this Presentation has not been prepared in accordance with United States generally accepted accounting principles ("GAAP"). Environmental Impact Acquisition Corporation ("ENVI") and GreenLight believe these non-GAAP measures of financial results provide useful information to management and investors regarding certain financial and business trends relating to GreenLight's financial condition and results of operations. You should review GreenLight's audited financial statements prepared in accordance with GAAP, which will be included in a combined registration statement and proxy statement to be filed with the SEC. Investor Presentation | 2021 GreenLight Biosciences. All rights reserved. GreenLight confidential. 4#5Environmental Impact (ENVI) platform overview Experienced Team with Proven Track Record Dan Coyne, CEO • Serves as Canaccord Genuity's Co-Head of U.S. Investment Banking and Global Head of Sustainability Investment Banking Helped develop CG's active Tech. & Sustainability Investment Banking teams ● • 26 years of banking experience with over 250 transactions closed with a focus on growth companies Board of Directors David Brewster Co-Founder EnerNOC Gov. Deval Patrick Former Governor Commonwealth of Mass. Marc Marano, CFO Managing Director in CG's Sustainability Investment Banking practice ● Jen Pardi Global Head of ECM Canaccord Genuity Investor Presentation | 2021 GreenLight Biosciences. All rights reserved. GreenLight confidential. • Closed 100+ transactions over past 15 years, focusing almost exclusively on Sustainability Dean Seavers Chair of the Board PG&E Sustainability-Focused Mission Partner with a high-growth, market leading business, propelled by a large & growing market opportunity and a business model supporting critical Sustainability initiatives Why GreenLight? Revolutionary RNA technology offers truly differentiated solutions ● ● ● ● Shared Passion & Vision ● ● Addressing multiple billion-dollar Agricultural & Health market opportunities with unique synthetic biology platform ● Compelling growth story with strong alignment with Sustainability & ESG initiatives; it is an Impact story Multi-decade focus on Sustainability Advised hundreds of growth companies on strategic transactions and capital raising activities Deep knowledge of relevant trends and thought leadership within Sustainability Commitment and mission to impact the world and its population positively LO 5#6GreenLight Bio. & Environmental Impact - Shared mission to deliver global Impact GreenLight Biosciences Andrey J. Zarur, Ph.D CEO Susan Keefe, MBA CFO Environmental Impact Acquisition Corp. Dan Coyne CEO & President Marc Marano CFO Key Highlights GreenLight Biosciences ("GreenLight" or the "Company") is a mission-driven synthetic biology platform developing RNA-based solutions for agriculture (plant health & pest control) and healthcare (vaccines & therapeutics) and various applications in these large segments ● ● ● GreenLight and Environmental Impact Acquisition Corp. ("ENVI") are combining to build out the Company's RNA production capabilities and advance its pipeline of 14 agriculture and human health products Existing GreenLight shareholders will roll 100% of their equity; several have also invested in PIPE ENVI has $207 million of cash in trust and a PIPE of $105 million Pro forma enterprise value of $1.2 billion for GreenLight ● GreenLight is targeting two of humanity's biggest challenges and largest economic opportunities: Food Security / Scarcity and Human Health ● GreenLight's platform is enabled by a proprietary, cell-free manufacturing process that produces high- quality RNA solutions in a more scalable, flexible and affordable manner than alternative technologies ENVI is excited to be GreenLight's aligned partner in its mission to address urgent food security needs and enable a healthier and "pandemic proof" future for humanity Investor Presentation | © 2021 GreenLight Biosciences. All rights reserved. GreenLight confidential. 6#7GreenLight's vision: Pave the way for a sustainable planet through widely available and affordable RNA Create Solutions to major challenges facing humanity through the rigorous application of biological sciences ANE x 12 29 cou 5 M ve osl Deliver 110219 Investor Presentation | © 2021 GreenLight Biosciences. All rights reserved. GreenLight confidential. MRN 2/26/21 A 52102 in PBS Als u Innovative RNA-based products for sustainable food production and human health, with our breakthrough synthetic biology platform Reward Our shareholders, employees, and stakeholders by growing sustainably and responsibly 7#8Greenlight exists to bring RNA solutions to solve some of the world's most pressing challenges Investor Presentation | © 2021 GreenLight Biosciences. All rights reserved. GreenLight confidential. We must end this pandemic, prepare for the next one, and develop innovative approaches to grave diseases in underserved parts of the world. Cutting-edge medi and healthcare should be available to all. We will be 9 billion humans on earth by 2037, increasingly adopting a middle-class lifestyle. For survival of humanity and the planet, our diets must be less carbon-intense. We must stop clearing land and reduce our use of chemical pesticides and fertilizers. 8#9GreenLight's pioneering platform offers affordable RNA solutions to the world We will enable affordable and globally scaled RNA applications in agriculture, and human health More affordable BAYER BAYER RNA Production Matrix syngenta Fermentation - not viable for RNA in agricultural or human use Cell-based GreenLight BIOSCIENCES™ Agriculture-Grade Investor Presentation | © 2021 GreenLight Biosciences. All rights reserved. GreenLight confidential. GreenLight BIOSCIENCES™ In-vitro transcription BIONTECH moderna Cell-free Chemical synthesis Alnylam CRISPRI editas Dicerna THERAPEUTICS MEDICINE Human-Grade Higher Quality 9#10Cell-free dsRNA production platform with unprecedented scale and reduced dependencies Opens a wide range of new and high-value applications for RNA in agriculture GreenLight's dsRNA proprietary manufacturing process for Agriculture Microbial RNA → (e.g., yeast) Depolymerize Enzyme (Nuclease) RNA Building → Blocks (NMPs) Cell-free RNA Production Energize & Polymerize Building Blocks ↑ Energy Instructions Enzymes (Polyphosphate) (DNA Template) (Kinases, Polymerase) Recovery GreenLight technology has removed barriers to RNA use in agriculture by delivering Cost less than $1/g dsRNA Scale +1,000 L batch for multi-kg-scale dsRNA Investor Presentation | © 2021 GreenLight Biosciences. All rights reserved. GreenLight confidential. ● Product Stability 25°C 2 years ● Quality, Ease of Use and Efficacy dsRNA Active Ingredient Formulation varies from product-to-product Agricultural RNA expertise enables new and newly accessible human health applications 10#11Our cell-free engine has overcome development and commercialization barriers for RNA We remove hurdles to implementing and scaling RNA for human, plant, and animal health Identify Bioinformatics MOLE Boh 11000016 10000 Develop and optimize Massive parallel trials High-throughput automation enables trialing of 1,000s of distinct RNA sequences for human health and food security Tools such as machine learning and proprietary algorithms identify best gene target candidates to protect food crops, design advanced medicines and vaccines for human and animal health Investor Presentation | © 2021 GreenLight Biosciences. All rights reserved. GreenLight confidential. Rochester facility dsRNA installed capacity at 500 kg per year with ready expansion to 1,000 kg Scale Commercialize at competitive prices Proprietary cell-free system enables scale up of RNA manufacturing, effectively, expediently and at lower costs 11#12Enabled by our platform, we will pursue a mix of collaborations and branded products Cost-effective production can open up numerous categories of GreenLight products and collaborations GreenLight's cell-free platform Markets Categories Products Agriculture and Food Production Cost, scale, stability, speed, quality dsRNA The ability to suppress protein synthesis Insecticide $17 bn5 Fungicide $16.5 bn5 Biomolecules, including sweeteners Agriculture company partnerships Food company partnerships (1) World Health Organization and MI4A, "Global Vaccine Market Report," (2020) (2) Fortune Business Insights, "Vaccines Market to Touch USD 105.87B by 2027," (2020) (3) Fortune Business Insights, "Monoclonal Antibody Market to Reach USD 350B by 2027," (2020) Investor Presentation | © 2021 GreenLight Biosciences. All rights reserved. GreenLight confidential. Human Health Scale, speed, modularity mRNA The instructions to make proteins Vaccines 2019: $33B1¹ 2020: $93B² Gene therapies 2021: $3.4B4 Pharma company partnerships (4) Grandview Research: "Gene Therapy Market Size, Share & Trends Analysis Report, 2021-2028" (5) AgBiolnvestor - AgBioSelect Database 12#13Nine projected product launches and multiple clinical milestones through 2026 Acquisitions and in-licensing deals have potential to further boost pipeline from GreenLight's engine GreenLight's cumulative TAM Colorado Potato Beetle Varroa Mite Botrytis Diamondback Moth Fusarium Powdery Mildew Two Spotted Spider Mite Covid Vaccine Seasonal Flu Supra-seasonal Flu Antibody therapy SCD Gene Therapy 2021 2022 $350M P1 Launch P2/P3 P1 2023 ~$33B 6 more agricultural programs planned for 2027 and beyond Investor Presentation | © 2021 GreenLight Biosciences. All rights reserved. GreenLight confidential. Launch 2024 ~$34B P2/P3 Launch P1 : EPA submission P1 P2/P3 : Clinical phase P1 2025 ~$40B Launch Launch Launch Launch P1 Partnership milestone 2026 O -$41B Launch Launch 13#14Our Team Exceptional management team with diverse public company expertise and proven track record of success 15 Companies founded AMGEN Charu Manocha MBA CPO ✪ MERCK Mir Andrey J. Zarur Ph.D CEO GM SOLID BIOSCIENCES veracyte novo nordisk DELPHI Robot KEURIG P&G Procter&Gamble sera care CHICAGO BOOTH Susan Keefe MBA CFO Edelman 8 Companies taken public VIRGINY pwc The Ogilvy New Hork Times Thomas Crampton SVP & Head Corporate Affairs DO MELIORA $ DANISCO. Carole Cobb MBA COO Genencor international, Inc inter Innovative by COUPONT Chemtura Harper Adams University UPL Investor Presentation | © 2021 GreenLight Biosciences. All rights reserved. GreenLight confidential. Arysta LifeScience Mark Singleton Ph.D SVP Technologies and External Innovation, Discovery Plant Health 100+ Years of public company experience Mit > kodiak venture partners Marta Ortega-Valle MBA CBO Human Health IBM Infosys jda. SAP David Kennedy General Counsel UCONN The University of criteo. UNITED KINGDOM-CHINA MALAYSIA gsk Lilly 1 v West NOVARTIS Amin Khan Ph.D Chief Scientific Officer, Human Health 14#15Plant and animal health platforms: Insecticides, fungicides and acaricides Investor Presentation | © 2021 GreenLight Biosciences. All rights reserved. GreenLight confidential. HUMAN HEALTH 15#16Conventional Pesticides GreenLight dsRNA Price and performance of first-ever foliar RNA product highly competitive with other premium solutions GreenLight product pipeline will address farmer, consumer, and environmental concerns Product Safety Specialist PPE often required for farmers GreenLight! Application submitted for standard handling equipment Effectiveness and use rate The active ingredients in many conventional pesticides for Colorado Potato Beetle-and many for other pests-have a use rate 50x that of GreenLight and face increasing resistance by pests. Effective control at extremely low active ingredient use rate for our first product, Colorado Potato Beetle, at just 4 g/acre. Roughly equivalent to a spoonful of sugar spread on football field. Investor Presentation | © 2021 GreenLight Biosciences. All rights reserved. GreenLight confidential. Toxicity and residue Environmental residue from chemical pesticides may endure for decades. e.g., Environmental DDT still easily detected 50 years being banned by EPA. Proven safe for nontarget insects, mammals at use rates 100x higher than our recommended rate. Degrades in water and soil within 3 days to benign, natural nucleotides. Biodiversity and pollinators Biodiversity concerns prompting governments bans on many widely used conventional pesticides. EPA banned 12 pesticides as toxic to beneficials and pollinators. EU has banned all outdoor uses of the 3 largest Group 4b neonicotinoids. No toxicity in normal use to honeybees, butterflies, beneficials, or other non-target organisms. PLANT HEALTH 16#17Rapid discovery to address emerging climate-driven farmer pain points Pipeline stretches from protecting honeybees to fresh produce and large-scale crops, a $10bn addressable market Program Colorado Potato Beetle Varroa Mite Botrytis Diamondback Moth Fusarium Powdery Mildew Fall Armyworm Pollen Beetle Two Spotted Spider Mite Asian Soybean Rust Black Sigatoka Wheat Septoria Vine Downy Mildew Total Collaborator WISCONSIN Discovery & lab studies Greenhouse trials Confirmatory trials Investor Presentation | © 2021 GreenLight Biosciences. All rights reserved. GreenLight confidential. POC field trials Regulatory submission Expected launch year 2022 2024 2025 2025 2025 2025 2027 2027 2026 2028 2028 2027 2028 TAM $350M $290M $1.2B $890M $950M $1.4B $1.9B $185M $1.1B $2.0B $2.4B $700M $440M >$10B *In negotiations on R&D collaboration with major agribusiness(es) PLANT HEALTH 17#18Colorado Potato Beetles decimate fields of potatoes, eggplants, and bell peppers Biodiversity-supporting solution to >$500M problem, from discovery to EPA submission in just four years Potato fields protected in 2020 field trials 4 g of GreenLight RNA per acre Untreated, 30 days 0 1cm 2 0 1cm 2 Investor Presentation | © 2021 GreenLight Biosciences. All rights reserved. GreenLight confidential. Meets farmers' buying criteria Equivalent efficacy to existing chemical- based treatments Cost competitive to other premium solutions Compatible with farmers' standard operating procedures Safe to use for operators and consumers Low to no detectable residue Does not harm beneficials or pollinators PLANT HEALTH 18#19While farmers benefit from effective new tool, they use standard application methods Sprayed from standard water tanks, degrades within days from field Application Mixed with water and sprayed using standard agricultural practice over crops, the dsRNA is used at a rate of a few grams per acre. This is less than one-tenth the rate at which conventional industrial chemicals are normally used on fields. Xxxxxxxxxx XXXXXXXXxX Investor Presentation | © 2021 GreenLight Biosciences. All rights reserved. GreenLight confidential. Mode of action Consumption of the dsRNA causes the Colorado Potato Beetle to stop eating the potatoes and expire from its own toxins. Environmental impact Studies show selected dsRNA affects only the Colorado Potato Beetle, leaving other beneficials -including honeybees, butterflies, earthworms, and the closely related ladybug-unaffected. The dsRNA itself degrades within days. PLANT HEALTH 19#20Honeybee colony devastation threatens crops and food supply GreenLight solution protects bees, beekeepers, and pollination-dependent crops Varroa destructor mite on honeybee pupa Investor Presentation | © 2021 GreenLight Biosciences. All rights reserved. GreenLight confidential. The 3 million commercial honeybee colonies in the United States are used to pollinate more than 100 crops annually that are worth an estimated $15 billion. Some crops, such as almonds, are almost entirely depe ent on pollination. The single greatest threat to honeybees, Varroa destructor mite, has been detected in up to 90% of US hives. The parasitic mite reproduces in hives, feeds on honeybees, and spreads disease, destroying colonies across North and South America, Europe, Asia, and Africa. Popular current applications result in bee injury and death. GreenLight's RNA-based solution, now in field trials, directly targets the Varroa mite to protect bees, beekeepers, and pollination-dependent crops. PLANT HEALTH 20#21Saving honeybees: Rapid roadmap to commercialization GreenLight acquired Bayer Intellectual Property portfolio that includes product to protect honeybees from Varroa mites B BAYER E R GreenLight acquires from Bayer Input materials and formulation development packaging validation December 10, 2020 wiet Light dsRNA production and GreenLight field trials in beehives Today Manufacture process and formulation locked Investor Presentation | © 2021 GreenLight Biosciences. All rights reserved. GreenLight confidential. Regulatory studies and registration submission 2022 Projected Product branding, marketing, and consumer education US EPA registration Product launch and first full-year sales 2024 T GreenLight BONC D PLANT HEALTH 21#22wor 10 Human health applications: Vaccines, therapies, antibodies Solutions for pandemics and more equitable access to novel therapies for grave diseases Investor Presentation | © 2021 GreenLight Biosciences. All rights reserved. GreenLight confidential. HUMAN HEALTH 22#23Human Health pipeline focused on large and significant markets mRNA design flexibility coupled with our production capability can enable rapid development of vaccines and therapies Application -CEH HED -CEH Vaccine Vaccine Gene Therapy Target Vaccine COVID-19 updated for VoC Seasonal influenza Sickle Cell Disease gene Antibody Antibody Therapy undisclosed Supra-seasonal influenza Collaborator ACADEMIC PARTNER ACADEMIC PARTNER BILL & MELINDA GATES foundation Funder ACADEMIC PARTNER ACADEMIC PARTNER Early Pre- clinical Pre-clinical Toxicity Pre-IND submitted to FDA* 11 * Clinical Development Phase 1 | Phase 2 | Phase 3 Investor Presentation | © 2021 GreenLight Biosciences. All rights reserved. GreenLight confidential. M M M M Anticipated Clinical Development Start Date H1 2022 H2 2022 TBD TBD H1 2024 Target timing to seek development/commercialization partnership Candidate selected and toxicology studies to be initiated HUMAN HEALTH 23#24CBH GreenLight's Covid-19 vaccine candidate has strong preclinical performance Comparable preclinical performance to other mRNA vaccines Company GreenLight BIOSCIENCES™ BIONTECH Pfizer moderna UREVAC the RNA peopleⓇ Mouse Neutralizing Ab Titer ~130,000 at 5µg dose Assay: Clinical Isolate -300 at 5µg dose Assay: Pseudovirus ~100 at 1µg dose Assay: Pseudovirus -5120 at 2µg dose Assay: Clinical Isolate CD4 Response ● ● • e ● e ● ● · . ● ● Th1-bias 1.5-3.5% of CD4 T cells producing cytokines Very little Th2 cytokines by ELISA Th1-bias Used ELISpot, not easily compared to flow cytometry Very little Th2 cytokines by ELISA Th1-bias 0.1-0.2% of CD4 T cells producing cytokines No ELISA data Flow data suggests a Th1 bias, but cytokine data suggests a mixed Th1/Th2 response ELISA data does not mirror flow cytometry well 0.2-0.6% of CD4 making Th1 cytokines CD8 Response Investor Presentation | © 2021 GreenLight Biosciences. All rights reserved. GreenLight confidential. 5-12.5% of CD8 T cells responding to restimulation by flow cytometry Used a different flow cytometry assay, difficult to compare results. 0.5-1.25% of CD8 T cells responding to restimulation by flow cytometry 5-15% of CD8 T Cells responding to restimulation by flow cytometry Sources: Vogel, A. et al."A prefusion SARS-CoV-2 spike RNA vaccine is highly immunogenic and prevents lung infection in non-human primates" (2020); Corbett, K.S., Edwards, D.K., Leist, S.R. et al. Nature (2020); Corbett, K.S. et al. NEJM (2020); Rauch, S. et al. "mRNA vaccine CVnCoV protects non-human primates from SARS-CoV-2 challenge infection" (2020); Rauch, S. et al.Nature (2021) HUMAN HEALTH 24#25CBH % BW Change from Baseline (Day 0) MEAN + SEM -10- -15 GreenLight's Covid-19 vaccine candidate Immune response protects against viral challenge Hamster body weight change on virus challenge 0 1 2 3 4 5 6 7 8 9 Days Post Challenge - LNP Control - Saline Control • 100 μg - · 30 μg -.· 5 μg 10 11 12 13 14 GLB-COV-2-043 All doses of GreenLight vaccine protected hamsters against weight loss following intranasal viral challenge IC50 (1/serum dilution) Investor Presentation | © 2021 GreenLight Biosciences. All rights reserved. GreenLight confidential. Neutralizing antibody levels in hamsters 100000 10000- 1000- 100- 10- 1 ns *** Mi H 100 μg 30 μg 5 μg GLB-COV-2-043 Day 21 (Pre-Boost) Day 39 (Post-Boost) GLuc Saline Controls Our GreenLight mRNA vaccine candidate induced high levels of binding and neutralizing antibodies at all doses tested HUMAN HEALTH 25#26CBH mRNA Influenza vaccines in development Success of COVID-19 RNA vaccines has renewed interest in influenza Company GreenLight BIOSCIENCES™ BIONTECH Pfizer moderna UREVAC the RNA people Translate BIO gsk SANOFI PASTEUR ARCTURUS therapeutics Agent Name GLB-flu-xx BNT-161 mRNA-1010 mRNA-1020 mRNA-1030 mRNA-1440 CV7301 Undisclosed Undisclosed LUNAR-FLU Description Seasonal influenza Seasonal influenza Seasonal influenza Seasonal influenza Seasonal influenza Avian influenza virus Seasonal influenza Universal influenza with Gates Funding Undisclosed Seasonal influenza Investor Presentation | © 2021 GreenLight Biosciences. All rights reserved. GreenLight confidential. Stage of Development Preclinical Phase 1 projected to begin 2H 2022 Preclinical Phase 1 to begin 2H 2021 Phase 1 to begin in 2021 Phase 1 to begin in 2021 Phase 1 to begin in 2021 Positive Ph1 reported in 2017 Preclinical Preclinical IND enabling Phase 1 to begin in 2021 Preclinical IND filing expected 1H 2022 HUMAN HEALTH 26#27CBH % BW Change from Baseline (Day 0) MEAN ± SEM Percentage body weight change on viral challenge Healthy Promising Green Light influenza vaccine candidate High levels of antibody production and protection against viral challenge Sick 10- 0- -10- -20- -30- 0 1 T 2 Baseline Cut-off for euthanasia 3 4 5 6 Days Post Challenge 7 8 9 10 10ug GLB quadrivalent 2 doses 1ug GLB quadrivalent 2 doses 10ug GLB quadrivalent 1 dose Saline Full protection against morbidity from influenza challenge in mice, as evidenced by no loss of weight observed in vaccinated animals Investor Presentation | © 2021 GreenLight Biosciences. All rights reserved. GreenLight confidential. Percent Survival Survival post-challenge with virus 100 90- 80- 70- 60- 50- 40- 30- 20- 10- 0+ 0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 Days Post Challenge GLB quadrivalent candidate GLB HA+NA candidate Saline Our vaccine candidates protect all mice from lethal influenza virus challenge HUMAN HEALTH 27#28GreenLight's vision to enable a global RNA manufacturing network Globally distributed units can address vaccine nationalism, adapt to variants, and offer non-pandemic advanced therapies RESEARCH LAB W 1. FILL & FINISH VACCINE PRODUCTION DATEN E org COVID SICKLE LESE FLU g COVID SICKLE CELL DISEASE FLU ********* DOMESTIC COVID CLE LL ASE U EXPORT Investor Presentation | © 2021 GreenLight Biosciences. All rights reserved. GreenLight confidential. Our vision is to enable the Africa, Asia, and Latin America regions to meet local demand through local production. A global mRNA vaccine manufacturing network could dramatically increase vaccine supplies, eliminate vaccine nationalism, respond quickly to variants, and offer non- pandemic RNA manufacturing for other indications. The network is planned to be distributed and interoperable, each facility will have less reliance on international supply chains to create vaccines for locally prevalent strains while being able to offer support for other facilities should need arise. GreenLight looks to deploy its proprietary RNA manufacturing process locally using modular design concepts that can constructed off-site and set up quickly in country. The facilities will be locally operated by a team of fewer than 100 staff to produce 1 billion vaccination courses per year. HUMAN HEALTH 28#29www Developing proof of concept for novel RNA-based approach to gene therapy Initial research into promising new avenue for Sickle Cell therapy with grant from the Bill & Melinda Gates Foundation RNA-encoded instructions ww Target specific vehicle ww Target m GreenLight gene therapy architecture targeting potential solutions that: Ribosome MM Target cell Can edit dividing and nondividing cells Do not require viral vectors Achieves long-lasting effect Are delivered direct to the patient Can be manufactured at scale Investor Presentation 2021 GreenLight Biosciences. All rights reserved. GreenLight confidential. Cell Nucleus Long lived expression of wild-type beta- globin gene Proprietary approach for integration of wild- type beta-globin gene 29#30MANUFACTURING OPERATIONS Inside GreenLight's production site for dsRNA Investor Presentation | © 2021 GreenLight Biosciences. All rights reserved. GreenLight confidential. 00 30#31GreenLight's commercial plant for agricultural RNA began operation in Q1 2021 Rochester NY-based RNA production facility currently outfitted for 500 kg output per year Investor Presentation | © 2021 GreenLight Biosciences. All rights reserved. GreenLight confidential. A Building 319 FEASTMAN BUSINESS PARK Building 350 Kodak Battery Coating Operation GreenLight Biosciences Kodalux 31#32Installed commercial capacity of 500 kg per year, ready for expansion to 1,000 kg per year Rochester site infrastructure supports further expansion up to 100 metric tons per year Investor Presentation | © 2021 GreenLight Biosciences. All rights reserved. GreenLight confidential. 32#33Dynamic workforce in place, with ready access to additional skilled labor Located in the biotech-centric Eastman Business Park, home to 100+ innovative companies Investor Presentation | © 2021 GreenLight Biosciences. All rights reserved. GreenLight confidential. 33#34IP and collaborators 34#35Extensive and rapidly expanding IP portfolio 145+ patents and 165+ applications Engine Patents RNA Platform 2 Foundational U.S. Patents 1 Foundational Japan Patent 61 Foundational Apps 10 Improvement Apps Process Control and Compound Production 53 9 Applications Patents RNA Platform Patents Human Health 2 Foundational Applications mRNA Platform App; RNA Gene Therapy App; Covid Vaccine Payload App Pipeline: Formulations, Payloads and Raw Materials Investor Presentation | © 2021 GreenLight Biosciences. All rights reserved. GreenLight confidential. RNA Crop Protection and Bee Health 88 Patents 72 Applications Pipeline: New Pests, Targets, and Formulations Sugar Platform Patents Sugar Platform 3₁ U.S. Patents 17 Applications Pipeline: New Pathways 35#36Our partners and collaborators Robert S. Langer MIT, Institute Professor Publicly-disclosed Collaborations WISCONSIN UNIVERSITY OF WISCONSIN-MADISON UPL OpenAg™ Dr. Drew Weissman Univ of Pennsylvania BAYER Life Sciences Advisors BAYER Luc Debruyne Former President GSK Global Vaccines MORNINGSIDE VENTURE PARTNERS Lupa Systems Investor Presentation | © 2021 GreenLight Biosciences. All rights reserved. GreenLight confidential. Dr. Mark Dybul Former Exec Dir Global Fund Major Investors Fall Line Capital Dr. Ted Ashburn Pres and CEO Oncorus s2gventures Baird Capital BAIRD CGC Cormorant Continental. Grain Company 36#37OPONI Stan pay at 0 HEY Opportunity Overview#38Plant health revenue - business plan ($ in millions) Target gross margin of 75-90%¹ for 2025 and beyond GLB Product Revenue R&D Collab. Revenue Platform Mfg. Revenue $0.0 2021E 0 $18.9 $0.6 2022E 0 $5.2 2023E Products in market 1 1. Target gross margin is for products GreenLight distributes directly; gross margin may differ for products GreenLight chooses to partner Investor Presentation | © 2021 GreenLight Biosciences. All rights reserved. GreenLight confidential. $119.7 2024E 2 2025E 7 $320.7 2026E 8 $489.3 2027E 8 PLANT HEALTH 38#39Human health revenue - business plan ($ in millions) Human health revenues largely expected in the form of royalties $1.51 2021E Milestone revenue Royalty revenue $40.0 2022E 1. 2021 Revenue reflects grant revenue $181.1 2023E $211.6 2024E Investor Presentation | © 2021 GreenLight Biosciences. All rights reserved. GreenLight confidential. $729.5 2025E $802.1 2026E $749.2 2027E HUMAN HEALTH 39#40Projected corporate financial metrics 2021-2025 ($ in millions) Revenue¹ EBITDA¹ Capital Expenditures Working Capital Investment 2021E $2 ($114) $14 $0 2022E $41 ($190) $71 $69 Investor Presentation | © 2021 GreenLight Biosciences. All rights reserved. GreenLight confidential. 2023E $186 ($11) $52 $64 2024E $231 ($23) $104 $61 2025E $849 $235 $32 $51 1. Non-GAAP financials based on management estimates. Modeling of EBITDA primarily reflects existing programs. Additional opportunities for investment will be considered and are not fully reflected in the EBITDA estimates. 40#41Transaction Summary & Pro Forma Equity Ownership Key Transaction Terms • Assumed a $1.2 billion enterprise valuation and gross cash proceeds of $312 million, inclusive of PIPE proceeds and cash in SPAC trust • GreenLight's current shareholders will own approximately 77% of the public company (assuming no redemptions or exercise of warrants) • After transaction costs, GreenLight would have ~$300 million of cash available on the balance sheet to fund growth and its manufacturing expansion (inclusive of the Company's existing net cash) Illustrative Cash Sources & Uses ($ in millions) Seller Rollover Estimated Cash in Trust (3) PIPE Proceeds Total Sources Equity Consideration to GreenLight Net Cash to Balance Sheet Estimated Transaction Costs Total Uses $ $1,200 207 105 $1,512 $1,200 282 30 $1,512 Pro Forma Valuation ($ in millions except per share data) Share Price Pro Forma Shares Outstanding (1) Equity Value Less: Net Cash from Transaction Less: Existing Net Cash on Balance Sheet (2) Implied Enterprise Value Post Money Ownership (4) GreenLight Equity 120.0 million shares (76.7% ownership) PIPE Investors 10.5 million shares (6.7% ownership) SPAC Public Shares 20.7 million shares (13.2% ownership) Investor Presentation | © 2021 GreenLight Biosciences. All rights reserved. GreenLight confidential. SPAC Founder Shares 5.2 million shares (3.3% ownership) 13.2% 3.3% 6.7% $10.00 156.4 $1,564 $282 $52 $1,230 76.7% (1)Shares outstanding and ownership at close includes 20,700,000 ENVI shares outstanding, 5,175,000 ENVI Founder shares, 120,000,000 shares issued to existing GreenLight shareholders, and approx. 10,500,000 shares issued to the PIPE investors. (2)Assumes $52 million in cash and conversion of any convertible notes, per the Company's draft unaudited financials as of 6/30/2021. (3)Cash in trust assumes no redemptions in connection with the business combination. (4)Post money equity ownership assumes no redemptions and excludes additions to the employee equity pool 41#42Anticipated use of proceeds $282M (Estimated Cash in Trust and PIPE Proceeds) Human Health Plant Health Platform & Corporate Development Investor Presentation | © 2021 GreenLight Biosciences. All rights reserved. GreenLight confidential. • Advance COVID-19 and seasonal flu vaccine candidates through clinical trials • Continue R&D efforts on further therapeutics • Launch pipeline of pest-protection products and first animal health product into market • Expand into other biological molecules (microbials, peptides, etc.) and applications • Build mRNA GMP manufacturing facility • Scale R&D processes, manufacturing capacity, and capabilities Buy versus make opportunities to accelerate growth and expand product/IP portfolio • Public company G&A costs ● 42#43GreenLight peer benchmarking CY2021E EV / Revenue CY2022E EV / Revenue 24.1x GINKGO BIOWORKS (1) THE ORGANISH COMPANY 13.8x GINKGO BIOWORKS (1) Ag & Food Production 15.8x CODEXIS PROTEIN ENGINEERING EXPERTS 13.4x CODEXIS® PROTEIN ENGINEERING EXPERTS 11.9x amyris 11.2x Peer average: 15.6x 10.6x BENSON HILL Peer average: 14.4x 25.3x 8.4x NM Z zymergen amyris BENSON HILL z zymergen 61.6x 8.9x (2) moderna BIONTECH (³) mange thepics moderna Healthcare 30.9x 12.2x Peer average: 31.9x 17.8x UREVAC the RNA people 7.4x Peer average: 8.4x (4) Translate BIO BIONTECH 17.4x (4) Translate BIO Source: Company filings and FactSet as of 8/6/21. (3) BioNTech 2021 EV / sales reflects EV/LTM revenues. Investor Presentation | © 2021 GreenLight Biosciences. All rights reserved. GreenLight confidential. (4) Multiples reflect 8/3/21 announcement of Sanofi definitive agreement to purchase Translate Bio at $38/share 5.2x UREVAC the RNA people (1) Ginkgo 2021E EV/ sales reflects 2024E revenues, and 2022E EV / sales reflects 2025E revenues based on investor presentation. (2) Moderna 2021 EV/ sales reflects EV / LTM revenues. 43#44GreenLight has significant upside potential ($ in millions) Ag & Food Production $19 $120 $321 $- $1 $5 2021E 2022E 2023E 2024E 2025E 2026E Ag & Food EV / 2026E revenue multiple: 14.4x Ag & Food implied enterprise value: $4,622 + + Investor Presentation | © 2021 GreenLight Biosciences. All rights reserved. GreenLight confidential. ($ in millions) $2 2021E Healthcare $40 2022E $181 2023E Healthcare EV / 2024E revenue multiple: 8.4x Healthcare implied enterprise value: $1,781 $212 2024E $6,403 44#45Summary of approach ● GreenLight indicative valuation ● Applies a range of 8.0x - 8.8x to GreenLight's 2024E Human Health revenue of $212m and 13.7x- 15.1x ($ in billions) to its 2026E Plant Health revenue of $321m to arrive at an implied future enterprise value Multiple range based off range of Healthcare EV/CY 2024E revenue trading multiple of 8.4x +/- 5% and Ag & Food Prod. EV/CY 2026E revenue trading multiple of 14.4x +/- 5% The future enterprise value is discounted 5 years back to 2021 at a 20% discount rate to arrive at an implied discounted enterprise value EV/ Revenue 2026E Metric $533m(1) Implied EV based on comparable companies current trading valuations Future enterprise value $6.7bn $6.1bn $6.4bn T Implied future enterprise value 11.4x 12.6x 2026E Revenue 1 1 I 1 Discounted enterprise value $2.6bn-- $2.7bn Source: Company filings and FactSet as of 8/6/21. (1) Reflects 2024E Human Health and 2026E Plant Health revenues. Investor Presentation | © 2021 GreenLight Biosciences. All rights reserved. GreenLight confidential. $2.4bn Implied discounted enterprise value (Discount at 5 periods: 20%) 4.6x - 5.1x 2026E Revenue Illustrative transaction valuation Enterprise value L-80-82% discount $1.2bn Enterprise value (Implied discount rate: -40%) 2.3x 2026E Revenue 45#46Why invest in us? 2 3 1 Cutting edge, proven technology to democratize RNA, making it available to solve problems in the world's most important markets: Agriculture, Food Production and Health Synthetic biology platform capable of producing RNA at scale, underscoring power of manufacturing at scale with highly competitive cost structure 4 Multiple product development milestones expected in the next 2 years Blue ocean opportunity representing $130bn in TAM across 18 products, many without meaningful competition 5 Best-in-class management team that has previously successfully scaled and commercialized biologics 46#47Corporate contacts page: Thomas Crampton GreenLight Biosciences SVP and Head of Corporate Affairs 200 Boston Ave Medford, Massachusetts 02155 Investor Presentation | © 2021 GreenLight Biosciences. All rights reserved. GreenLight confidential. 47#48Appendix: Additional Human Health details Investor Presentation | © 2021 GreenLight Biosciences. All rights reserved. GreenLight confidential. 48#49Proprietary GreenLight approach consolidates key processes under single roof Modular, scalable and with reduced logistical complexity 3rd Party Capping Nucleotides ● ATP CTP GTP UTP or MeYTP GreenLight mRNA Human Health commercial process today Cell-free production of mRNA RNA polymerase Purification Fermentation Microbial strain DNA Template Linearization Purification Fermentation Microbial strain Investor Presentation | © 2021 GreenLight Biosciences. All rights reserved. GreenLight confidential. Purification Formulation Proprietary enzyme and fermentation processes generate required essential materials, including T7 and DNA template. In-house processes for purification of mRNA and its formulation into an LNP. This approach reduces interdependencies, accelerates availability of materials, and creates advantages in terms of controlled, reliable, and fast production of doses. Fill and Finish 49#50Next generation GreenLight approach further consolidates processes Potential elements allow for additional logistical simplicity and cost reductions Polyphosphate СМР → СТР UMP → UTP GMP → GTP AMP → ATP ^^^^^^ 5 Kinases Microbial strain GreenLight mRNA Human Health manufacturing process Next Gen Capping Nucleotides Cell-free production of mRNA RNA polymerase Purification Fermentation Microbial strain DNA Template Linearization Purification Fermentation Microbial strain Investor Presentation | © 2021 GreenLight Biosciences. All rights reserved. GreenLight confidential. Purification Formulation Fill and Finish 50#51CBH GreenLight Covid vaccine has considerable potential Endemic Covid expected to drive global vaccine demand to ~$20B in 2027 Covid-19 Challenge Only 21 doses for every 100 people have been administered worldwide Periodic booster dose may be necessary Widespread Covid-19 vaccinations will not be achieved until 2023 Late 2021 Source: Economist Intelligence Unit, January 2021 Mid 2022 Late 2022 from early 2023 Our Proposed Solution Covid-19 variant updated vaccine candidate Proprietary RNA manufacturing platform Investor Presentation | © 2021 GreenLight Biosciences. All rights reserved. GreenLight confidential. Target profile advantages compared to traditional vaccine production • Integrated, scalable, proprietary manufacturing platform less dependent on key raw materials supply Small production footprint to produce billions of doses of Covid-19 vaccines or annual boosters rapidly adapted to address new variants of concern • Cost-competitive, especially for middle- and low-income countries HUMAN HEALTH 51#52CBH GreenLight influenza vaccine tackles significant current problems Need for greater efficacy and shorter cycle times for seasonal vaccine updates ~$3.3B market Influenza Challenge Mismatch between vaccine strains and circulating seasonal strains due to strain selection occurring ~6 months prior to human dosing The egg-based production process of current influenza vaccines often cause viral mutations that result in reduced efficacy Slow in a pandemic response setting due to inadequate supply of chicken eggs • Typical efficacy is ~40-70% Our Proposed Solution Seasonal influenza vaccine candidates Proprietary RNA manufacturing platform Investor Presentation | © 2021 GreenLight Biosciences. All rights reserved. GreenLight confidential. Target profile advantages compared to traditional vaccine production ● Shorter cycle time from strain selection to vaccine production due to removal of live pathogen and egg adaptation steps Greater reliability in producing vaccine formulation that matches circulating strain as exact antigen(s) is encoded Timely scalable production in case of pandemic influenza strain is possible ● Potential for higher efficacy with novel antigen design HUMAN HEALTH 52#53Appendix: Summary Risk Factors Investor Presentation | © 2021 GreenLight Biosciences. All rights reserved. GreenLight confidential. 53#54Summary Risk Factors Risks relating to the proposed business combination: • GreenLight has a limited operating history, which makes it difficult to evaluate our current business and prospects and increases the risk of investment. • We have a history of net losses, and we may not achieve or maintain profitability. • If we do not develop and introduce new products that obtain regulatory approval and achieve market acceptance, we will not be able to generate or grow revenues. • We will incur significant expenses to develop products and cannot assure you that we can achieve a return on that investment. We face significant competition and many of our competitors have substantially greater financial, technical, supply chain and other resources than we do. • • Our business, financial results and reputation in the marketplace may suffer upon the loss of a significant customer or partner. • Our ability to bring agricultural products to market successfully depends on achieving and maintaining the price competitiveness of RNA anticipated to be produced by our RNA platform. • We are subject to numerous and rapidly changing federal, state, local and international laws and regulations related to our products, and the failure to comply with any of these laws and regulations, or failure to comply with new or changed laws and regulations, could adversely affect our business and our financial condition. • Information technology systems are critical to our business and interruptions, or security incidents associated with those systems could cause significant disruption to our business as well as financial and reputational harm. • Loss of key personnel could delay our programs, harm our development efforts and adversely affect our business and results of operations. Investor Presentation | © 2021 GreenLight Biosciences. All rights reserved. GreenLight confidential. 54#55Summary Risk Factors Risks relating to the proposed business combination (cont'd): • The unpredictability of the spread and treatment of the SARS-CoV-2 virus and its variants could materially harm our business prospects. • Intellectual property rights including patents and patent applications involve highly complex legal and factual questions, which, if determined adversely to us, could negatively impact our competitive position or ability to bring products to market or cause us to incur liabilities. • We do not and will not seek to protect our intellectual property rights in all jurisdictions and we may not be able to adequately enforce our intellectual property rights in those jurisdictions where we do seek protection. • The anticipated size of the addressable markets for our products may not materialize. • Our projections are subject to significant assumptions and we may not achieve them and our future results could be materially different than anticipated. • A material weakness in financial controls resulted from the classification of the ENVI warrants as components of equity instead of as derivative liabilities and the ENVI warrants have been reclassified as a step to remedy the material weakness. If we identify additional material weaknesses in the future or otherwise fail to maintain an effective system of internal control over financial reporting, this may result in material misstatements of our consolidated financial statements or failure to meet our periodic reporting obligations. • Our results of operations and financial condition are subject to management's accounting judgments and estimates, as well as changes in accounting policies. We will incur increased costs as a result of operating as a public company, and our management will devote substantial time to new compliance initiatives. Investor Presentation | © 2021 GreenLight Biosciences. All rights reserved. GreenLight confidential. 55#56Summary Risk Factors Risks relating to the proposed business combination (cont'd): • The consummation of the merger is subject to a number of conditions and if those conditions are not satisfied or waived, the merger agreement may be terminated in accordance with its terms and the merger may not be completed. ● If the Merger benefits do not meet the expectations of investors or securities analysts, the market price of ENVI's securities or, following the consummation of the Merger, the combined company's securities may decline. • Potential legal proceedings in connection with the Merger, the outcomes of which are uncertain, could delay or prevent the completion of the Merger. • If ENVI's due diligence investigation of the Company's business was inadequate and material risks are not uncovered, stockholders of ENVI following the Merger could lose some or all of their investment. • New GreenLight's stock price may change significantly following the merger and you could lose all or part of your investment as a result. • Because there are no current plans to pay cash dividends on New GreenLight Common Stock for the foreseeable future, you may not receive any return on investment unless you sell your common stock for a price greater than that which you paid for it. • Future sales, or the perception of future sales, by New GreenLight or its stockholders in the public market following the merger could cause the market price for New GreenLight Common Stock to decline. • Certain of New GreenLight's stockholders, including the Sponsor, may engage in business activities which compete with New GreenLight or otherwise conflict with New GreenLight's interests. • There is no guarantee that a ENVI public stockholder's decision whether to redeem their shares for a pro rata portion of the Trust Account will put such stockholder in a better future economic position. Redemptions by ENVI public stockholders will result in less funding being available to New GreenLight and may cause a condition to the merger to fail. Investor Presentation | © 2021 GreenLight Biosciences. All rights reserved. GreenLight confidential. 56